TY  - JOUR
AU  - Heyland, Daren K
AU  - van Zanten, Arthur R H
AU  - Grau-Carmona, Teodoro
AU  - Evans, David
AU  - Beishuizen, Albertus
AU  - Schouten, Jeroen
AU  - Hoiting, Oscar
AU  - Bordejé, Maria Luisa
AU  - Krell, Kenneth
AU  - Klein, David J
AU  - Gonzalez, Jesus
AU  - Perez, Aitor
AU  - Brown, Randy
AU  - James, Joyce
AU  - Harris, M Scott
AU  - Investigators of the PROMOTE LP101-CL-201 Trial
PY  - 2019
DO  - 10.1007/s00134-019-05593-2
UR  - https://hdl.handle.net/10668/24351
T2  - Intensive care medicine
AB  - Enteral feeding intolerance (EFI) is a frequent problem in the intensive care unit (ICU), but current prokinetic agents have uncertain efficacy and safety profiles. The current study compared the efficacy and safety of ulimorelin, a ghrelin agonist,...
LA  - en
KW  - Enteral feeding intolerance
KW  - Gastric residual volume
KW  - Metoclopramide
KW  - PROMOTE
KW  - Ulimorelin
KW  - Volume-based feeding
KW  - APACHE
KW  - Adult
KW  - Aged
KW  - Antiemetics
KW  - Canada
KW  - Critical Illness
KW  - Double-Blind Method
KW  - Enteral Nutrition
KW  - Female
KW  - Gastric Emptying
KW  - Humans
KW  - Intensive Care Units
KW  - Macrocyclic Compounds
KW  - Male
KW  - Metoclopramide
KW  - Middle Aged
KW  - Netherlands
KW  - Organ Dysfunction Scores
KW  - Spain
KW  - United States
TI  - A multicenter, randomized, double-blind study of ulimorelin and metoclopramide in the treatment of critically ill patients with enteral feeding intolerance: PROMOTE trial.
TY  - research article
VL  - 45
ER  -